Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes.
作者信息
Fala Loretta
出版信息
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):92-5.
Abstract
摘要
相似文献
1
Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes.捷诺达（恩格列净），一种钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，获得美国食品药品监督管理局（FDA）批准用于治疗2型糖尿病患者。
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):92-5.
2
3
Bilateral gangrene of fingers in a patient on empagliflozin: First case report.恩格列净治疗患者出现双侧手指坏疽：首例病例报告。
World J Diabetes. 2019 Feb 15;10(2):133-136. doi: 10.4239/wjd.v10.i2.133.
4
5
Empagliflozin: A Review in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的评价。
Drugs. 2018 Jul;78(10):1037-1048. doi: 10.1007/s40265-018-0937-z.
6
SGLT2 inhibitors: new reports.钠-葡萄糖协同转运蛋白2抑制剂：新报道
Med Lett Drugs Ther. 2015 Oct 12;57(1479):139-40.
7
▼ Empagliflozin, diabetes and outcomes.▼ 恩格列净、糖尿病与结局。
Drug Ther Bull. 2016 Jul;54(7):78-81. doi: 10.1136/dtb.2016.6.0411.
8
The role of empagliflozin in the management of type 2 diabetes by patient profile.恩格列净在根据患者情况管理2型糖尿病中的作用。
Ther Clin Risk Manag. 2015 May 5;11:739-49. doi: 10.2147/TCRM.S71762. eCollection 2015.
9
Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.恩格列净，一种用于治疗2型糖尿病的钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：证据综述
Ann Pharmacother. 2015 May;49(5):582-98. doi: 10.1177/1060028015573564. Epub 2015 Feb 23.
10
Empagliflozin in type 1 diabetes.恩格列净用于1型糖尿病治疗
Diabetes Metab Syndr Obes. 2019 Aug 22;12:1555-1561. doi: 10.2147/DMSO.S194688. eCollection 2019.
引用本文的文献
1
Empowering Pharmacists in Type 2 Diabetes Care: Opportunities for Prevention, Counseling, and Therapeutic Optimization.增强药剂师在2型糖尿病护理中的作用：预防、咨询及治疗优化的机遇
J Clin Med. 2025 May 29;14(11):3822. doi: 10.3390/jcm14113822.
2
The impact of empagliflozin and metformin on cardiac parameters in patients with mid-range ejection fraction heart failure without diabetes.恩格列净和二甲双胍对射血分数中间值的心衰伴非糖尿病患者心脏参数的影响。
J Med Life. 2024 Jan;17(1):57-62. doi: 10.25122/jml-2023-0340.
3
Empagliflozin repurposing in Parkinson's disease; modulation of oxidative stress, neuroinflammation, AMPK/SIRT-1/PGC-1α, and wnt/β-catenin pathways.恩格列净在帕金森病中的再利用；调节氧化应激、神经炎症、AMPK/SIRT-1/PGC-1α 和 Wnt/β-连环蛋白通路。
Inflammopharmacology. 2024 Feb;32(1):777-794. doi: 10.1007/s10787-023-01384-w. Epub 2023 Dec 1.
4
Insights from the molecular docking analysis of SGLT2 and FIMH to combat uropathogenicity.钠-葡萄糖协同转运蛋白2（SGLT2）和1型菌毛（FimH）分子对接分析对抗尿道致病性的见解
Bioinformation. 2022 Nov 30;18(11):1044-1049. doi: 10.6026/973206300181044. eCollection 2022.
5
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.关于抗糖尿病药物相关体重减轻的综合综述
Life (Basel). 2023 Apr 14;13(4):1012. doi: 10.3390/life13041012.
6
Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events.恩格列净对2型糖尿病（T2DM）合并射血分数降低的心力衰竭（HFrEF）且心血管事件高危患者的安全性、有效性和获益评估。
Cureus. 2022 Dec 28;14(12):e33070. doi: 10.7759/cureus.33070. eCollection 2022 Dec.
7
Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study.恩格列净作为抗糖尿病治疗附加药物在沙特2型糖尿病患者中的疗效和安全性：一项前瞻性、开放标签、观察性研究。
J Clin Med. 2022 Aug 16;11(16):4769. doi: 10.3390/jcm11164769.
8
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.钠-葡萄糖协同转运蛋白 2 抑制剂在动物模型中炎症过程调节中的作用。
Int J Mol Sci. 2022 May 18;23(10):5634. doi: 10.3390/ijms23105634.
9
Empagliflozin Relaxes Resistance Mesenteric Arteries by Stimulating Multiple Smooth Muscle Cell Voltage-Gated K (K) Channels.恩格列净通过刺激多个平滑肌细胞电压门控钾 (K) 通道来舒张阻力性肠系膜动脉。
Int J Mol Sci. 2021 Oct 7;22(19):10842. doi: 10.3390/ijms221910842.
10
Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy.钠-葡萄糖协同转运蛋白2抑制剂恩格列净通过调节AMPK-mTOR信号通路介导的自噬改善舒尼替尼诱导的心脏功能障碍。
Front Pharmacol. 2021 Apr 29;12:664181. doi: 10.3389/fphar.2021.664181. eCollection 2021.
本文引用的文献
1
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.恩格列净作为 2 型糖尿病患者二甲双胍的附加治疗：一项 24 周、随机、双盲、安慰剂对照试验。
Diabetes Care. 2014 Jun;37(6):1650-9. doi: 10.2337/dc13-2105. Epub 2014 Apr 10.
2
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.恩格列净单药治疗联合西他列汀作为活性对照药物用于 2 型糖尿病患者：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Diabetes Endocrinol. 2013 Nov;1(3):208-19. doi: 10.1016/S2213-8587(13)70084-6. Epub 2013 Sep 9.
3
AACE comprehensive diabetes management algorithm 2013.美国临床内分泌医师协会2013年综合糖尿病管理算法
Endocr Pract. 2013 Mar-Apr;19(2):327-36. doi: 10.4158/endp.19.2.a38267720403k242.
4
Economic costs of diabetes in the U.S. in 2012.2012 年美国糖尿病的经济成本。
Diabetes Care. 2013 Apr;36(4):1033-46. doi: 10.2337/dc12-2625. Epub 2013 Mar 6.
5
Executive summary: Standards of medical care in diabetes--2013.执行摘要：《2013年糖尿病医疗护理标准》
Diabetes Care. 2013 Jan;36 Suppl 1(Suppl 1):S4-10. doi: 10.2337/dc13-S004.
6
Standards of medical care in diabetes--2013.《糖尿病医疗护理标准——2013》
Diabetes Care. 2013 Jan;36 Suppl 1(Suppl 1):S11-66. doi: 10.2337/dc13-S011.
7
Understanding the kidneys' role in blood glucose regulation.了解肾脏在血糖调节中的作用。
Am J Manag Care. 2012 Jan;18(1 Suppl):S11-6.
8
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.肾脏在葡萄糖稳态中的作用：使血糖正常化的新途径。
Diabetes Obes Metab. 2012 Jan;14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x.
9
Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.2050 年美国成年人口糖尿病负担预测：发病率、死亡率和糖尿病前期患病率的动态建模。
Popul Health Metr. 2010 Oct 22;8:29. doi: 10.1186/1478-7954-8-29.
Zotero 插件